Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01890889
Other study ID # 065
Secondary ID
Status Recruiting
Phase N/A
First received June 27, 2013
Last updated November 21, 2013
Start date July 2013
Est. completion date December 2013

Study information

Verified date November 2013
Source Integrative Health Technologies, Inc.
Contact Patricia L Keith
Phone 210-824-4200
Email hmrcenterstudy@gmail.com
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of a food-source nutrient containing bitter orange by comparing changes 45 blood chemistries and self-reported quality of life.


Description:

To evaluate the safety and efficacy of a food-source nutrient by comparing changes in total cholesterol levels, 44 other blood chemistries, and self-reported quality of life as a function of consuming two different functional-food supplements versus a placebo in a 60-day study.

Upon completion of the pre-study screening, and after having received an explanation of the requirements, risks and benefits, and completing the informed consent interview with the research coordinator, subjects will execute a written informed consent. Subjects will be randomly assigned to one of three study groups.

Relevant Background Information.

A factor leading to development of vascular disease, a leading cause of death in industrialized nations, is elevated serum cholesterol. It is estimated that 19% of Americans between the ages of 20 and 74 years of age have high serum cholesterol. However, in an analysis of 10,000 test results in our database from subjects similar to those who are likely to participate in this study, we found 37% of subjects had TC scores between 200 and 250 and 10.3% above 250.

The most prevalent form of vascular disease is arteriosclerosis, a condition associated with the thickening and hardening of the arterial wall. The regulation of whole-body cholesterol homeostasis involves the regulation of intestinal cholesterol absorption, cellular cholesterol trafficking, a modulation of cholesterol biosynthesis, bile acid biosynthesis, steroid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins. Regulation of intestinal cholesterol absorption has proven to be an effective means by which to regulate serum cholesterol levels.

Ad-Chol-Pre (ACP) is a functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe. In previous unpublished pilot studies examining the safety and efficacy of ACP include:

- ACP was shown to produce a statistically inhibition of [3H]-Cholesterol absorption from 50 ug/ml (P<0.05) in NPC1L1 over-expressing HepG2 cell lines as compared to an inhibition of 10ug/ml with Ezetimibe alone.

- I preliminary unpublished animal studies, ACP was shown to significantly inhibit radiolabelled cholesterol. ACP was found to significantly lower total cholesterol (38% ~56%) and LDL cholesterol (46~57%) in bloods from animals fed who had been fed a high fat diet for 6 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2013
Est. primary completion date November 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- be an English-speaking male or female at least 18 years of age;

- have a total cholesterol level between 200 mg/dL and 250mg/dL

- have a LDL level between 100 mg/dL and 160 mg/dL

- not have allergic reactions to eggs or egg products

- not have consumed cholesterol-lowering drugs within 2 months of starting the study

- agree to follow the requirements of the study as set forth in this Informed Consent

- agree to withdraw from the study if becoming pregnant during the study.

Exclusion Criteria:

- do not speak English;

- are under 18 years of age;

- have a total cholesterol level below 200 mg/dL or above 250 mg/dL

- have a LDL level below 100 mg/dL or above 160 mg/dL

- have allergic reactions to eggs or egg products

- have consumed cholesterol-lowering drugs within 2 months of starting the study

- are pregnant or nursing;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)


Intervention

Dietary Supplement:
Ad-Chol-Pre

Half-dose Ad-Chol-Pre

Other:
Defatted egg yolk without the active ingredient of the other two interventions


Locations

Country Name City State
United States Integrative Health Technologies San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Integrative Health Technologies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in Total Cholesterol and LDL levels at 30 days 0 and 30 days Yes
Primary Change from baseline in Total Cholesterol and LDL levels at 60 days 0 and 60 days Yes
Primary Change from mid-point in Total Cholesterol and LDL levels at 60 days 30 and 60 days Yes
Secondary Blood Chemistry Measurements Remaining lipids, Complete Blood Count, Metabolic Panel, Thyroid Stimulating Hormone, Cardio C-reactive Protein 0, 30, and 60 days Yes
Secondary Self-reported Quality of Life 0, 30, and 60 days Yes
Secondary Number of participants with adverse effects up to 60 days Yes
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT04640012 - Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects Phase 1
Completed NCT03213288 - Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status N/A
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02979704 - A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia Phase 2/Phase 3
Completed NCT02569814 - A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin Phase 1
Completed NCT02280590 - Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia Phase 4
Completed NCT02428998 - Safety for 24 Weeks Intake of Korean Red Ginseng in Adults N/A
Completed NCT01678183 - Financial Incentives for Medication Adherence N/A
Completed NCT01426412 - A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol Phase 1
Completed NCT01694446 - Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose N/A
Completed NCT01131832 - Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols Phase 4
Completed NCT00534105 - Lipid Metabolism in Gestational Diabetes N/A
Completed NCT00758303 - A Study to Evaluate the Lipid Regulating Effects of TRIA-662 Phase 2/Phase 3
Recruiting NCT00408824 - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study) N/A
Terminated NCT00299169 - Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes Phase 4
Completed NCT00362206 - Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin Phase 3
Completed NCT00414986 - Using Learning Teams for Reflective Adaptation for Diabetes and Depression N/A
Completed NCT00381992 - Risk Assessment of Long-Haul Truck Drivers N/A